Navigation Links
Commercial Insurance Buyers Benefit From Ample Capacity
Date:9/30/2009

KANSAS CITY, Mo. and LONDON, Sept. 30 /PRNewswire/ -- In its newly published Lockton Market Update, global insurance broker Lockton says that the markets are in a relative state of calm and insurance buyers are benefitting from generally stable pricing. The online update includes snapshots of more than two dozen markets with the latest trends facing risk managers, chief financial officers and other executives.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090415/CG99351LOGO)

Lockton reports in an overview that U.S. P&C insurers saw results rebound to show a small profit in the first half of the year, after seeing an operating loss in the first quarter. Underwriting losses have declined since last year, but shrinking written premiums continue to pressure results. While underwriters have greater incentive to maintain pricing discipline than during the last several years, competitive pressures have, by and large, not allowed insurers much room to increase rates.

While a number of negative events hit insurers hard during the past year, this has not yet resulted in the broad hardened market that many anticipated. Lockton reports that variation by line and industry continues, and some of the more difficult markets during the past six months may become less volatile. Ample capacity will likely extend the favorable market in most lines for companies that have strong financials and clear loss histories.

Highlights from the report include:


SOURCE Lockton Market Update
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Axial Biotech Announces Commercial Availability of SCOLISCORE(TM) AIS Prognostic Test
2. Ironwood Appoints Thomas McCourt As Chief Commercial Officer and Senior Vice President of Marketing and Sales
3. Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsens Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
4. Cornerstone Therapeutics Receives Approval to Acquire Commercial Rights to the Antibiotic Factive(R)
5. avVaa World Health Care Products, Inc. Announces the completion of its first week of DRTV 120/60 second test commercials for Neuroskin(R) Psoriasis Relief
6. Orexigen(R) Therapeutics Appoints Mark Booth Chief Commercial Officer
7. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
8. SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS
9. Jatropha Couple Oil Crop Cultivation Technology Commercially Released
10. Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
11. BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...O, Nov. 20 Veridiam (www.veridiam....size company category at the 2009 Workplace Excell...iego Society for Human Resources Management and re... practices. ,, Veridiam was one of nine winners...ompanies, honored at the recent awards ceremony. S...
(Date:11/20/2009)...TLE, Nov. 20 Cell Therap...d today that the Ninth Circuit Court of Appeals re...CTI should be allowed to pursue all of its claims ...he District Court for trial. CTI filed a complain... reimbursement consultant for CTI,s product TRISEN...
(Date:11/19/2009)...N, Nov. 19 Danish Prince Joachim i...ethanol plant in Kalundborg, Denmark, on Wednesday...first and largest 2nd generation ethanol demonstra... are used in the plant,s innovative process for co...nisco, was the first to market with commercial enz...
(Date:11/19/2009)..., Nov. 19 NeoStem, Inc. ...nt the following letter to its shareholders, discu...09, of China Biopharmaceuticals Holdings, Inc. (CH...d in the People,s Republic of China. The merger gi...yre Pharmaceutical Co. Ltd., CHBP,s primary operat...
Breaking Biology Technology:Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category 2Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2DONG Energy and Inbicon Inaugurate One of the World's Largest Demo Plants for 2nd Generation Biofuel 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3
...mproved Technology Will Provide the Early Detectio...in Fish Farms and Wild Stocks -, HAMILTON, New Ze...une,17 ZyGEM Corp Ltd. and DIAGNOTEC S.A. today a...oduce molecular diagnostics for the,detection of i...ly pathogen,that attacks salmon and other fish spe...
...h Throughput Technology Identifies DNA Variations ... and Test Genome, OMAHA, Neb., June 17 Transgeno...t it is developing SURVEYOR,Endonuclease Adaptor-l...,throughput enabling technology for whole genome a...reference genome and a test genome. SEAL is,design...
...VER, June 17 Corgenix Medical Corporation,(OTC Bu...keter of,diagnostic test kits, announced today the...Charles H. Miranda, M.D., F.A.C.P., F.A.A.P., to i...nda join Luis Lopez, M.D., Corgenix Chairman and,C...ntific advisory board,members to three., "These t...
Other Biology Technology:ZyGEM and DIAGNOTEC Collaborate on Diagnostics for Detecting a Devastating Virus Attacking Salmon 2ZyGEM and DIAGNOTEC Collaborate on Diagnostics for Detecting a Devastating Virus Attacking Salmon 3Transgenomic Introduces SURVEYOR(R) Endonuclease Adaptor-Ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation 2Transgenomic Introduces SURVEYOR(R) Endonuclease Adaptor-Ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation 3Transgenomic Introduces SURVEYOR(R) Endonuclease Adaptor-Ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation 4Corgenix Expands Scientific Advisory Board 2Corgenix Expands Scientific Advisory Board 3
(Date:11/20/2009)...November 19, 2009 The estimated 4.6 million Ameri...k of developing respiratory symptoms due to poor a...naire study undertaken earlier this year by invest...eterinary Medicine. , The studywhich polled more...50 percent of individuals working in barns complai...
(Date:11/20/2009)...able in German . , In the current online is.... Stefanie Eyerich and Dr. Kilian Eyerich together...n and Istituto Dermopatico dell,Immacolata in Rome...sents a milestone on the way to developing new tre... as psoriasis and allergic reactions and potential...
(Date:11/20/2009)...new study, researchers report that a class of hear...ful, or harmful, effect on the heart, depending on...pears in the journal Circulation Research , found...d beta-receptors on the heart muscle offer the mos...rget only the beta-receptors can actually undermin...
Breaking Biology News(10 mins):Barn personnel experience higher-than-average rates of respiratory symptoms 2Discovery of new type of immune cells regulating inflammation in chronic diseases 2Carvedilol shown to have unique characteristics among beta blockers 2American Dental Association Web Survey Offers Chance at 24150 Gift Certificate 54263 1American Dental Association Web Survey Offers Chance at 24150 Gift Certificate 54263 2Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 54261 1Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 54261 2Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 54261 3Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 54261 4Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 54261 5Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 54261 6Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 54261 7Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results 54261 8Viral Genetics Scientist Presents Potential New Treatment for Drug Resistant Brain Tumors at Aspen Symposium 13511 1Viral Genetics Scientist Presents Potential New Treatment for Drug Resistant Brain Tumors at Aspen Symposium 13511 2Viral Genetics Scientist Presents Potential New Treatment for Drug Resistant Brain Tumors at Aspen Symposium 13511 3
...lot-dissolving medication that is administered to ...ay help to reduce the risk of amputation following...ne issue of Archives of Surgery, one of the JAMA/A...ed essentially the same for the past 25 years, acc...Today, traditional therapy consists of tissue rewa...
...at the University of Central Florida is proving pr...ucoma, an eye disease that can cause blindness and...particle can safely get past the blood-brain barri...delivery,” said Sudipta Seal, an engineering profe... Processing and Analysis Center and the Nanoscienc...
...ions and other diseases of the brain is the blood-...ed therapeutic drugs from reaching the brain. Gran...ctious Diseases, part of the National Institutes o...tide) from the rabies virus can carry a strip of t... administration. Once delivered to the nerve cells...
Other Biology News:Clot-dissolving agent may be beneficial in treatment of severe frostbite 2UCF nanoparticle offers promise for treating glaucoma 2Blood-brain barrier breached by new therapeutic strategy 2
...y and flexibility press-to-seal silicone isolators...cher. They are available either pre-cut to specifi...n be easily trimmed to prepare customized enclosur...oxic and can be used to isolate cells in culture d...
... found in Complete Freund's Adjuvant so it minimiz... Freund's Adjuvant is used for the boost injecti...er-in-oil emulsions of immunogens. Antigens in w...ing antibody responses which can be attributed to ...
Keyhole Limpet Hemocyanin DNP-KLH (Keyhole Limpet Hemocyanin), KLH (Keyhole Limpet Hemocyanin) conjugated/tagged from Biosearch Technologies
6-keto Prostaglandin F1alpha-d4 from Cayman Chemical
Biology Products: